CRTX vs. NKGN, BCLI, PLUR, SRZN, INKT, TARA, ACHL, AIM, ZIVO, and EVAX
Should you be buying Cortexyme stock or one of its competitors? The main competitors of Cortexyme include NKGen Biotech (NKGN), Brainstorm Cell Therapeutics (BCLI), Pluri (PLUR), Surrozen (SRZN), MiNK Therapeutics (INKT), Protara Therapeutics (TARA), Achilles Therapeutics (ACHL), AIM ImmunoTech (AIM), ZIVO Bioscience (ZIVO), and Evaxion Biotech A/S (EVAX). These companies are all part of the "medical" sector.
NKGen Biotech (NYSE:NKGN) and Cortexyme (NASDAQ:CRTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, community ranking, risk, valuation, earnings and dividends.
76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 63.2% of Cortexyme shares are owned by institutional investors. 20.0% of NKGen Biotech shares are owned by insiders. Comparatively, 27.9% of Cortexyme shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
NKGen Biotech has higher revenue and earnings than Cortexyme.
In the previous week, Cortexyme's average media sentiment score of 0.67 beat NKGen Biotech's score of 0.00 indicating that NKGen Biotech is being referred to more favorably in the media.
NKGen Biotech has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Cortexyme has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.
Cortexyme received 154 more outperform votes than NKGen Biotech when rated by MarketBeat users.
Cortexyme's return on equity of 0.00% beat NKGen Biotech's return on equity.
Summary
NKGen Biotech beats Cortexyme on 5 of the 9 factors compared between the two stocks.
Get Cortexyme News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cortexyme Competitors List
Related Companies and Tools
